On March 15, 2019, Hospira, Inc., a Pfizer company, initiated a voluntary recall of certain lots of 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) to the Hospital/Institution level due to the presence of particulate matter, confirmed as glass. This recall was classified as a Class I Recall on April 10, 2019, by the Food and Drug Administration.

These products are being recalled as a precaution. To date, no harmful side effects have been reported due to this recall.

For more information or details on recalled lots, visit www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/hospira-inc-issues-voluntary-nationwide-recall-84-sodium-bicarbonate-injection-usp-due-presence.